SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, to develop an autoinjector for clinical and potential commercial supply of MoonLake’s Nanobody® sonelokimab based on SHL Medical’s Molly® autoinjector technology.

Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in cyno samples

Robert (Bobbie) Dressen, CEO of Medical Alley, and Brigit van Dijk – van de Reijt, CEO of the Brabant Development Agency (BOM), on behalf of ROM NL, signed a Memorandum of Understanding (MOU) in the presence of Minister Kuipers of Health, Welfare and Sport.

As a result of the agreement, MammaTyper® will become part of the Sysmex Life Science portfolio in 13 territories across EMEA, including the UK, Ireland and the majority of mainland Europe.

3DSecret funded by European Innovation Council’s Pathfinder Open 2022, established under the EU Horizon Europe program Consortium to leverage novel microfluidic technology to culture 3D cancer models for multi-parametric analysis, to inform cancer diagnostic and therapeutic development